<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02068846</url>
  </required_header>
  <id_info>
    <org_study_id>12-0036</org_study_id>
    <secondary_id>1R21DE023046-01A1</secondary_id>
    <nct_id>NCT02068846</nct_id>
  </id_info>
  <brief_title>BK Virus in Salivary Gland Disease: Treating the Potential Etiologic Agent</brief_title>
  <official_title>BK Virus in Salivary Gland Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Dental and Craniofacial Research (NIDCR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to analyze BK viral infection in salivary gland diseases;
      specifically, to determine a definitive relationship between BK Virus and HIV associated
      salivary gland disease (HIVSGD). Participants are adults HIV+SGD+ who will be randomized 1:1
      to receive BK Virus antiviral (ciprofloxacin) or placebo for 28 days. Salivary
      function/protein secretion will be correlated with BK polyomavirus titers. It is expected
      that patients with HIV+SGD+ will have elevated oral BK polyomavirus viral loads and will
      benefit from Ciprofloxacin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study duration is 12 weeks with a baseline visit, a visit at 4 weeks and a visit at 12
      weeks. At baseline participants are randomized to Ciprofloxacin or placebo and take the drug
      or placebo for 28 days. At subsequent visits BK polyomavirus presence and salivary gland
      function will be assessed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2014</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BK Viral Status in Saliva at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Oral fluids will be assessed for evidence of BK Virus replication to determine whether Cipro administration inhibits BK Virus replication in participants with HIVSGD. Oral fluids will be assessed by real-time PCR to determine BK Virus status as positive or negative.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>BK Viral Status in Saliva at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Oral fluids will be assessed for evidence of BK Virus replication to determine whether Cipro administration inhibits BK Virus replication in participants with HIVSGD. Oral fluids will be assessed by real-time PCR to determine BK Virus status as positive or negative.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Unstimulated Salivary Flow Rate at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>To determine whether salivary gland function is improved or restored with the administration of Cipro in participants with HIVSGD. After sitting at rest for 1 minute, participants collect drool using 50-mL conical tubes. The 5-minute unstimulated whole saliva flow rate recorded and collected. Salivary hypofunction is defined as unstimulated whole saliva flow rate ≤ 0.1 mL/min. Normal salivary function is defined as &gt; 0.1 mL/min.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unstimulated Salivary Flow Rate at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>To determine whether salivary gland function is improved or restored with the administration of Cipro in participants with HIVSGD. After sitting at rest for 1 minute, participants collect drool using 50-mL conical tubes. The 5-minute unstimulated whole saliva flow rate recorded and collected. Salivary hypofunction is defined as unstimulated whole saliva flow rate ≤0.1 mL/min. Normal salivary function is defined as &gt;0.1 mL/min.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Dry Mouth &quot;Yes/No&quot; at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Participants were asked &quot;Have you noticed any change in your salivary glands or in the dryness of your mouth&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Dry Mouth &quot;Yes/No&quot; at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Participants were asked &quot;Have you noticed any change in your salivary glands or in the dryness of your mouth&quot;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>HIV</condition>
  <condition>Salivary Gland Disease</condition>
  <condition>Benign Lymphoepithelial Lesion</condition>
  <arm_group>
    <arm_group_label>Ciprofloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active treatment twice daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo treatment twice daily for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin</intervention_name>
    <description>Over encapsulated Ciprofloxacin 500 mg will be taken twice daily for 28 days.</description>
    <arm_group_label>Ciprofloxacin</arm_group_label>
    <other_name>Cipro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will over encapsulated to match active treatment, taken twice daily for 28 days.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV positive with Salivary Gland Disease

          -  Ability to read and understand English

        Exclusion Criteria:

          -  Allergy to the family of fluoroquinolones (including ciprofloxacin)

          -  Currently taking tizanidine

          -  Concurrently taking antiacids containing magnesium hydroxide or aluminum hydroxide

          -  Current use of Theophylline

          -  Previous tendon disorder such as Rheumatoid arthritis

          -  History of seizures

          -  Current use of phenytoin

          -  Current use of glyburide

          -  Current use of methotrexate

          -  Severe renal impairment (known creatinine clearance &lt; 30 or on dialysis)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Webster-Cyriaque, DDS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of North Carolina School of Dentistry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of North Carolina School of Dentistry</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>February 19, 2014</study_first_submitted>
  <study_first_submitted_qc>February 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2014</study_first_posted>
  <results_first_submitted>June 17, 2019</results_first_submitted>
  <results_first_submitted_qc>June 17, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 11, 2019</results_first_posted>
  <last_update_submitted>June 17, 2019</last_update_submitted>
  <last_update_submitted_qc>June 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Salivary Gland Disease</keyword>
  <keyword>Benign Lymphoepithelial Lesion</keyword>
  <keyword>BK Polyomavirus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salivary Gland Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofloxacin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ciprofloxacin</title>
          <description>Active treatment twice daily for 28 days
Ciprofloxacin: Over encapsulated Ciprofloxacin 500 mg will be taken twice daily for 28 days.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo treatment twice daily for 28 days
Placebo: Placebo will over encapsulated to match active treatment, taken twice daily for 28 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ciprofloxacin</title>
          <description>Active treatment twice daily for 28 days
Ciprofloxacin: Over encapsulated Ciprofloxacin 500 mg will be taken twice daily for 28 days.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo treatment twice daily for 28 days
Placebo: Placebo will over encapsulated to match active treatment, taken twice daily for 28 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.6" lower_limit="37" upper_limit="69"/>
                    <measurement group_id="B2" value="52.3" lower_limit="49" upper_limit="57"/>
                    <measurement group_id="B3" value="52.5" lower_limit="37" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White non-Hispanic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BK Virus Status in Saliva</title>
          <description>Oral fluids will be assessed for evidence of BK Virus replication to determine whether Cipro administration inhibits BK Virus replication in participants with HIV associated salivary gland disease (HIVSGD). Oral fluids will be assessed by real-time polymerase chain reaction (PCR) to determine BK Virus status as positive or negative.</description>
          <population>Data were not analyzed for one participant who discontinued</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="7"/>
                    <count group_id="B3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>BK Virus positive</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>BK Virus negative</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Unstimulated Salivary Flow Rate</title>
          <description>To determine salivary gland function at Baseline. After sitting at rest for 1 minute, participants collect drool using 50-mL conical tubes. The 5-minute unstimulated whole saliva flow rate recorded and collected. Salivary hypofunction is defined as unstimulated whole saliva flow rate ≤ 0.1 mL/min. Normal salivary function is defined as &gt; 0.1 mL/min.</description>
          <population>Data not collected because participant missed scheduled visit</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="7"/>
                    <count group_id="B3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal salivary function</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Salivary Hypofunction</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>BK Viral Status in Saliva at Week 4</title>
        <description>Oral fluids will be assessed for evidence of BK Virus replication to determine whether Cipro administration inhibits BK Virus replication in participants with HIVSGD. Oral fluids will be assessed by real-time PCR to determine BK Virus status as positive or negative.</description>
        <time_frame>Week 4</time_frame>
        <population>Two participants withdrew prior to Week 4</population>
        <group_list>
          <group group_id="O1">
            <title>Ciprofloxacin</title>
            <description>Active treatment twice daily for 28 days
Ciprofloxacin: Over encapsulated Ciprofloxacin 500 mg will be taken twice daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo treatment twice daily for 28 days
Placebo: Placebo will over encapsulated to match active treatment, taken twice daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>BK Viral Status in Saliva at Week 4</title>
          <description>Oral fluids will be assessed for evidence of BK Virus replication to determine whether Cipro administration inhibits BK Virus replication in participants with HIVSGD. Oral fluids will be assessed by real-time PCR to determine BK Virus status as positive or negative.</description>
          <population>Two participants withdrew prior to Week 4</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>BK Virus positive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>BK Virus negative</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>BK Viral Status in Saliva at Week 12</title>
        <description>Oral fluids will be assessed for evidence of BK Virus replication to determine whether Cipro administration inhibits BK Virus replication in participants with HIVSGD. Oral fluids will be assessed by real-time PCR to determine BK Virus status as positive or negative.</description>
        <time_frame>Week 12</time_frame>
        <population>Two participants withdrew prior to Week 4</population>
        <group_list>
          <group group_id="O1">
            <title>Ciprofloxacin</title>
            <description>Active treatment twice daily for 28 days
Ciprofloxacin: Over encapsulated Ciprofloxacin 500 mg will be taken twice daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo treatment twice daily for 28 days
Placebo: Placebo will over encapsulated to match active treatment, taken twice daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>BK Viral Status in Saliva at Week 12</title>
          <description>Oral fluids will be assessed for evidence of BK Virus replication to determine whether Cipro administration inhibits BK Virus replication in participants with HIVSGD. Oral fluids will be assessed by real-time PCR to determine BK Virus status as positive or negative.</description>
          <population>Two participants withdrew prior to Week 4</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>BK Virus positive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>BK Virus negative</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Unstimulated Salivary Flow Rate at Week 4</title>
        <description>To determine whether salivary gland function is improved or restored with the administration of Cipro in participants with HIVSGD. After sitting at rest for 1 minute, participants collect drool using 50-mL conical tubes. The 5-minute unstimulated whole saliva flow rate recorded and collected. Salivary hypofunction is defined as unstimulated whole saliva flow rate ≤ 0.1 mL/min. Normal salivary function is defined as &gt; 0.1 mL/min.</description>
        <time_frame>Week 4</time_frame>
        <population>Two participants withdrew prior to Week 4 and one participant did not perform salivary flow collection.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciprofloxacin</title>
            <description>Active treatment twice daily for 28 days
Ciprofloxacin: Over encapsulated Ciprofloxacin 500 mg will be taken twice daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo treatment twice daily for 28 days
Placebo: Placebo will over encapsulated to match active treatment, taken twice daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Unstimulated Salivary Flow Rate at Week 4</title>
          <description>To determine whether salivary gland function is improved or restored with the administration of Cipro in participants with HIVSGD. After sitting at rest for 1 minute, participants collect drool using 50-mL conical tubes. The 5-minute unstimulated whole saliva flow rate recorded and collected. Salivary hypofunction is defined as unstimulated whole saliva flow rate ≤ 0.1 mL/min. Normal salivary function is defined as &gt; 0.1 mL/min.</description>
          <population>Two participants withdrew prior to Week 4 and one participant did not perform salivary flow collection.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Normal salivary function</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Salivary hypofunction</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Unstimulated Salivary Flow Rate at Week 12</title>
        <description>To determine whether salivary gland function is improved or restored with the administration of Cipro in participants with HIVSGD. After sitting at rest for 1 minute, participants collect drool using 50-mL conical tubes. The 5-minute unstimulated whole saliva flow rate recorded and collected. Salivary hypofunction is defined as unstimulated whole saliva flow rate ≤0.1 mL/min. Normal salivary function is defined as &gt;0.1 mL/min.</description>
        <time_frame>Week 12</time_frame>
        <population>Two participants withdrew prior to Week 4 and two participants did not perform salivary flow collection.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciprofloxacin</title>
            <description>Active treatment twice daily for 28 days
Ciprofloxacin: Over encapsulated Ciprofloxacin 500 mg will be taken twice daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo treatment twice daily for 28 days
Placebo: Placebo will over encapsulated to match active treatment, taken twice daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Unstimulated Salivary Flow Rate at Week 12</title>
          <description>To determine whether salivary gland function is improved or restored with the administration of Cipro in participants with HIVSGD. After sitting at rest for 1 minute, participants collect drool using 50-mL conical tubes. The 5-minute unstimulated whole saliva flow rate recorded and collected. Salivary hypofunction is defined as unstimulated whole saliva flow rate ≤0.1 mL/min. Normal salivary function is defined as &gt;0.1 mL/min.</description>
          <population>Two participants withdrew prior to Week 4 and two participants did not perform salivary flow collection.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Normal salivary function</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Salivary hypofunction</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Dry Mouth &quot;Yes/No&quot; at Week 4</title>
        <description>Participants were asked &quot;Have you noticed any change in your salivary glands or in the dryness of your mouth&quot;</description>
        <time_frame>Week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ciprofloxacin</title>
            <description>Active treatment twice daily for 28 days
Ciprofloxacin: Over encapsulated Ciprofloxacin 500 mg will be taken twice daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo treatment twice daily for 28 days
Placebo: Placebo will over encapsulated to match active treatment, taken twice daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Dry Mouth &quot;Yes/No&quot; at Week 4</title>
          <description>Participants were asked &quot;Have you noticed any change in your salivary glands or in the dryness of your mouth&quot;</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Change = Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Change = No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Dry Mouth &quot;Yes/No&quot; at Week 12</title>
        <description>Participants were asked &quot;Have you noticed any change in your salivary glands or in the dryness of your mouth&quot;</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ciprofloxacin</title>
            <description>Active treatment twice daily for 28 days
Ciprofloxacin: Over encapsulated Ciprofloxacin 500 mg will be taken twice daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo treatment twice daily for 28 days
Placebo: Placebo will over encapsulated to match active treatment, taken twice daily for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Dry Mouth &quot;Yes/No&quot; at Week 12</title>
          <description>Participants were asked &quot;Have you noticed any change in your salivary glands or in the dryness of your mouth&quot;</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Change = Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Change = No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ciprofloxacin</title>
          <description>Active treatment twice daily for 28 days
Ciprofloxacin: Over encapsulated Ciprofloxacin 500 mg will be taken twice daily for 28 days.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo treatment twice daily for 28 days
Placebo: Placebo will over encapsulated to match active treatment, taken twice daily for 28 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jennifer Webster-Cyriaque, DDS, PhD</name_or_title>
      <organization>University of North Carolina at Chapel Hill</organization>
      <phone>(919) 537-3492</phone>
      <email>jwebster@email.unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

